Note: This is Part 1 of a two part series covering academic research with Dr. Mark Noble of the University of Rochester. 
This article, Part 1, covers both background and current research with Dr. Noble.

Part 2 . In his own words Dr. Noble reports on disturbing Levaquin toxicity findings he made in 2010 after our FQ team initiated research with him.

It goes without saying that academic research is vitally important to the fluoroquinolone (FQ) community and our goal to reveal the true impact that FQs are having on our society.

In this critical area of academic research, Dr. Mark Noble of the University of Rochester was one of three major academic researchers that saw the true impact of FQ toxicity and agreed to work with us on behalf of the FQ community. Dr. Noble is a delightfully altruistic and a talented professional. University_of_Rochester_seal_Small

Dr. Noble is Professor of Neurology, Genetics, and Neurobiology and Anatomy at University of Rochester School of Medicine and is Director of the University of Rochester Stem Cell and Regenerative Medicine Institute. He is one of the pioneers of stem cell research and directs research on multiple topics, including spinal cord injury, genetic diseases and cancer.


Our team initially contacted Dr. Noble in 2010 due to his research with chemotherapeutic pharmaceuticals such as 5FU, chemo brain, and the capabilities of his lab. After we presented Dr. Noble with some interesting scientific Levaquin, Dr. Noble agreed to perform initial lab tests using Levaquin.

In the fall of 2010, Dr. Linda Martin and Dr. Paul Schnipelsky, a retired pharmaceutical researcher and executive with PhD’s in Chemistry, traveled to meet Dr. Noble at his U of R lab. At this meeting, Dr. Noble presented results of his initial research. The results were very interesting indeed. I will soon be releasing this initial toxicity information on Levaquin that was produced by Dr. Noble in the fall of 2010.

The initial meeting between Dr. Noble, Dr. Schnipelsky, and Dr. Martin, combined with Dr. Noble’s initial findings, has led to a long standing working relationship that has included regular phone conferences attended by science professionals from within the FQ community. We are very pleased that our initial contact with Dr. Noble in 2010 was the impetus for his FQ research today.

Current Research Directions

We recently held a planned phone conference with Dr. Noble to get an update on various aspects of his FQ research. Mark-Noble

• Dr. Noble is currently preparing mice that are phenotypically predisposed with higher TNF (Tumor Necrosis Factors). These mice will be used to identify atypical inflammation involved in both muscular/skeletal and CNS issues. These mice will be used to study inflammatory patterns in FQ exposure.

• Dr. Noble has deferred lysosomal FQ related mouse experiments initially planned in the fall of 2014, pending further data collection. Because Dr. Noble still feels strongly that lysosomal issues play an important part in FQ toxicity, he has asked our group to collect data regarding certain specific symptoms possibly experienced by floxies that are directly related to lysosomal issues. This is something that we will begin soon.

• Dr. Noble has assisted us with a submission for the upcoming FDA Meeting.

Much has been happening in the FQ community on many fronts from the media, to the FDA, to research. Sometimes information, especially on the internet, moves at a frenetic pace and the facts get distorted or lost in the translation.

It is vitally important for the FQ community to have true, factual data regarding these issues in order to appear credible and stay well informed.

Our FQ team, which is the same team that solicited Dr. Noble in 2010, will continue to work closely with Dr. Noble, to bring you factual information on his academic FQ research.

Stay tuned to My Quin Story as I will be sure to inform the FQ community of any pertinent developments with Dr. Noble, Dr. Golomb, and Dr. Bennett.

You can read part 2 of this article, here.